A patient with lung adenocarcinoma and with a homozygous stop-gain mutation in BARD1 (G320*) and a duplication event in RBBP8 (e3–4 duplication) was also classified as HRD by HRDetect but not by CHORD. Here, RBBP8 is linked to lung adenocarcinoma.